Spectral Medical (TSE:EDT)
TSX:EDT
Want to see TSE:EDT full AI Analyst Report?
EDT Stock Chart & Stats
C$1.39
-C$0.01(-1.75%)
At close: 4:00 PM EST
C$1.39
-C$0.01(-1.75%)
Day’s Range― - ―
52-Week RangeC$0.77 - C$1.84
Previous CloseN/A
Volume37.78K
Average Volume (3M)78.93K
Market Cap
C$404.92M
Enterprise ValueC$437.01M
Total Cash (Recent Filing)C$1.92M
Total Debt (Recent Filing)C$22.27M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 07, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding293,418,980
10 Day Avg. Volume98,063
30 Day Avg. Volume78,934
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-5.93
Price to Sales (P/S)169.36
P/FCF Ratio-42.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$3.50Price Target Upside151.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$2.67M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent TTM revenue growth (13.1%) indicates improving market adoption of the PMX therapy and related diagnostics. Sustained top-line momentum provides a path to scale, helps absorb fixed costs, and is a durable lever for improving cash generation if margins and commercialization execute over the next several quarters.
Focused Product & Market NicheA focused therapy-plus-diagnostic strategy targeting endotoxin in sepsis creates a differentiated clinical value proposition. Combining targeted diagnostics with a therapeutic device can improve patient selection, support better clinical outcomes and payer acceptance, and establish a defensible niche in critical care over the medium term.
Lean Operating BaseA small headcount signals a lean cost structure and operational agility, limiting fixed overhead as the company scales commercial and clinical efforts. This structural lightness can extend runway per dollar raised and enable focused investment in high-impact areas like pivotal trials and targeted commercialization.
Bears Say
Highly Stressed Balance SheetThe large equity deficit and minimal asset base limit financial flexibility and increase refinancing and dilution risk. With debt materially exceeding assets, the company is structurally dependent on external capital to operate, which constrains strategic optionality and heightens execution risk over the coming quarters.
Sustained Cash BurnPersistent negative operating and free cash flow of about $11.1M TTM consumes liquidity and forces reliance on financing. Until margins improve or revenues scale substantially, continued cash burn threatens program funding, commercialization cadence, and increases probability of dilutive capital raises within a medium-term horizon.
Extremely Weak Profitability & MarginsDeeply negative gross and net margins reflect a cost structure that currently overwhelms revenue. Without structural improvements to COGS, pricing, or operating leverage, revenue growth is unlikely to translate into sustainable profitability, leaving the company exposed to prolonged cash consumption and investor dilution.
Spectral Medical News
EDT FAQ
What was Spectral Medical’s price range in the past 12 months?
Spectral Medical lowest stock price was C$0.77 and its highest was C$1.84 in the past 12 months.
What is Spectral Medical’s market cap?
Spectral Medical’s market cap is C$404.92M.
When is Spectral Medical’s upcoming earnings report date?
Spectral Medical’s upcoming earnings report date is Aug 07, 2026 which is in 76 days.
How were Spectral Medical’s earnings last quarter?
Spectral Medical released its earnings results on May 08, 2026. The company reported -C$0.01 earnings per share for the quarter, the consensus estimate of -C$0.01 by C$0.
Is Spectral Medical overvalued?
According to Wall Street analysts Spectral Medical’s price is currently Undervalued.
Does Spectral Medical pay dividends?
Spectral Medical pays a Notavailable dividend of C$0.12 which represents an annual dividend yield of N/A. See more information on Spectral Medical dividends here
What is Spectral Medical’s EPS estimate?
Spectral Medical’s EPS estimate is -0.01.
How many shares outstanding does Spectral Medical have?
Spectral Medical has 293,418,980 shares outstanding.
What happened to Spectral Medical’s price movement after its last earnings report?
Spectral Medical reported an EPS of -C$0.01 in its last earnings report, expectations of -C$0.01. Following the earnings report the stock price went up 5.147%.
Which hedge fund is a major shareholder of Spectral Medical?
Currently, no hedge funds are holding shares in TSE:EDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Spectral Medical
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
EDT Stock 12 Month Forecast
Average Price Target
C$3.50
▲(151.80% Upside)
Technical Analysis
Cipher Pharmaceuticals
―
BioMark Diagnostics
―
kneat.com
―
Profound Medical
―
Sona Nanotech Inc
―
Options Prices
Currently, No data available
---